Senior Medical Manager, Cardiovascular & Emerging Therapy Areas

Join Novo Nordisk in Warsaw, Poland as a Senior Medical Manager in the Cardiovascular & Emerging Therapy Areas. This newly created position plays a key role in the CETA team, collaborating with clinical, medical and commercial colleagues to ensure strategic alignment and synergy.

Your responsibilities include:

• Plan and execute medical strategies and activities with a strong focus on omnichannel engagement (OCE).
• Identify and segment relevant Key Opinion Leaders (KOLs), digital opinion leaders, and collaborate with patient advocacy groups (PAGs) where needed.
• Cascade and adapt medical plans, including publication plans and real‑world evidence (RWE) plans.
• Liaise with relevant professional associations, including managing congress activities.
• Seek opportunities and provide advice to obtain market and patient pathway insights to support internal medical and commercial decision‑making.

Approximately 20 % travel is required.

Your skills and qualifications:

• Advanced degree (MD, PharmD, or PhD) in medical, pharmaceutical, or life‑sciences field and minimum 3‑5 years of experience in Medical Affairs or a related field within the pharmaceutical or biotech industry.
• Relevant therapy area knowledge, with priority on geriatric indication expertise; experience in cardiology or neurology is a plus.
• Proven experience in driving omnichannel activities and managing approval processes.
• Project‑based activity and ability to successfully deliver initiatives as well as work effectively in a cross‑functional and multicultural environment.
• Experience in multiple market regulatory environments is a plus.

Willingness to travel within the country and internationally is a prerequisite. Proficiency in English is required; additional languages such as Polish are a plus.

We’re looking for a curious & self‑driven person who combines medical expertise with a commercial mindset, strong communication and relationship building skills, and openness to innovation.

Deadline: 18 November 2025 – early submission encouraged.